State of New Jersey Common Pension Fund D Has $2.12 Million Stock Position in Amedisys, Inc. (NASDAQ:AMED)

State of New Jersey Common Pension Fund D increased its stake in Amedisys, Inc. (NASDAQ:AMED) by 14.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 23,324 shares of the health services provider’s stock after acquiring an additional 2,967 shares during the quarter. State of New Jersey Common Pension Fund D’s holdings in Amedisys were worth $2,118,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Rhumbline Advisers lifted its stake in shares of Amedisys by 1.6% in the fourth quarter. Rhumbline Advisers now owns 91,298 shares of the health services provider’s stock worth $8,289,000 after acquiring an additional 1,412 shares during the period. ABC Arbitrage SA acquired a new position in shares of Amedisys in the fourth quarter worth approximately $2,522,000. Blue Trust Inc. lifted its stake in shares of Amedisys by 55.1% in the fourth quarter. Blue Trust Inc. now owns 349 shares of the health services provider’s stock worth $34,000 after acquiring an additional 124 shares during the period. Empowered Funds LLC acquired a new position in shares of Amedisys in the fourth quarter worth approximately $318,000. Finally, State of Alaska Department of Revenue lifted its stake in shares of Amedisys by 448.3% in the fourth quarter. State of Alaska Department of Revenue now owns 20,737 shares of the health services provider’s stock worth $1,882,000 after acquiring an additional 16,955 shares during the period. 94.36% of the stock is owned by institutional investors and hedge funds.

Amedisys Price Performance

Shares of AMED opened at $90.43 on Friday. Amedisys, Inc. has a 52-week low of $82.15 and a 52-week high of $98.95. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.19 and a current ratio of 1.19. The business’s 50 day moving average price is $90.74 and its two-hundred day moving average price is $93.40. The firm has a market cap of $2.96 billion, a PE ratio of 35.88, a price-to-earnings-growth ratio of 1.80 and a beta of 0.73.

Wall Street Analysts Forecast Growth

Separately, Stephens reissued an “equal weight” rating and issued a $101.00 price target on shares of Amedisys in a research note on Wednesday, February 12th. Five equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $100.75.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.